Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S, Okazaki E
Department of Pathology, Niigata University School of Medicine, Japan.
Cancer. 1990 Dec 15;66(12):2628-35. doi: 10.1002/1097-0142(19901215)66:12<2628::aid-cncr2820661227>3.0.co;2-1.
The authors studied data of combination assays of tumor markers, because simultaneous elevation of different types of tumor markers in the serum was puzzling. They interpreted such phenomena regarding cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. The tissue expression of the antigens was compared with preoperative serum levels. Several different factors were found to cause the simultaneous elevation of two or three of these markers in the serum. Furthermore, even when the levels of some of the tumor markers were raised in the serum, the ovarian tumor did not always produce the marker by itself. This study indicates that immunohistochemical identification of a marker in tumor tissue is prerequisite to the use of that marker in the serum to monitor disease status.
作者研究了肿瘤标志物联合检测的数据，因为血清中不同类型肿瘤标志物同时升高令人困惑。他们针对卵巢肿瘤中的癌抗原125、癌胚抗原和糖类抗原19-9对这种现象进行了解释。将这些抗原的组织表达与术前血清水平进行了比较。发现有几个不同因素可导致血清中这两种或三种标志物同时升高。此外，即使血清中某些肿瘤标志物水平升高，卵巢肿瘤也并非总是自身产生该标志物。这项研究表明，在肿瘤组织中对标志物进行免疫组化鉴定是在血清中使用该标志物监测疾病状态的前提条件。
